Visión generalGráficoNoticiasTraderScreen

Soc. Generale Knock-Out ATO/  DE000SV91SW8  /

EUWAX
11/10/2024  9:37:18 Diferencia- Bid22:00:34 Ask22:00:34 Subyacente Precio de ejercicio Fecha de expiración Tipo de opción
6.92EUR - -
Volumen de oferta: -		 -
Tamaño/ Volumen/ Formato de Ask: -		 Atos SE 7.5949 - 31/12/2078 Put
GlobeNewswire 28/08 Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
GlobeNewswire 21/08 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 21/08 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 20/08 Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Publi...
GlobeNewswire 14/08 Stevie® Awards Announce Winners in The 21st Annual International Business Awards® from Across the Gl...
GlobeNewswire 12/08 Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 30/07 HUMAN Releases The Quadrillion Report: 2024 Cyberthreat Benchmarks, Uncovers Nearly 150 Million Comp...
GlobeNewswire 22/07 Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE...
GlobeNewswire 02/07 Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
GlobeNewswire 28/06 Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combin...
GlobeNewswire 17/06 Atossa Set to Join Russell 3000® Index Effective June 28, 2024
GlobeNewswire 11/06 Pythian Welcomes Brooks Borcherding as Chief Executive Officer
GlobeNewswire 05/06 Atossa to Present at the Sidoti Small-Cap Investor Conference
GlobeNewswire 30/05 Groundbreaking Technology Solves Major Problem of User Lockouts During MFA Resets
GlobeNewswire 28/05 NetLogistik Wins Partner Leadership Award from Blue Yonder
GlobeNewswire 28/05 Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast...
GlobeNewswire 16/05 Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats
GlobeNewswire 15/05 Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...
GlobeNewswire 15/05 Calian Reports Record Results for the Second Quarter
GlobeNewswire 13/05 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 13/05 NVIDIA Grace Hopper Ignites New Era of AI Supercomputing
GlobeNewswire 07/05 Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
GlobeNewswire 29/04 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire 15/04 Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...
GlobeNewswire 11/04 Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference